August 22, 2018

Rexahn partners with Merck on combo study in TNBC

By PBR Staff Writer

The partnership will assess Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy in a phase 2 study in patients with metastatic triple negative breast cancer (TNBC). The trial has been